Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Colchicine,Niclosamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : CSIR-Indian Institute of Chemical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CSIR and Laxai Life Sciences have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 pati...
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 12, 2021
Lead Product(s) : Colchicine,Niclosamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : CSIR-Indian Institute of Chemical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Niclosamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : CSIR-Indian Institute of Chemical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins
Details : The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2021
Lead Product(s) : Niclosamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : CSIR-Indian Institute of Chemical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir,Colchicine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study will combine and repurpose antivirals and host-directed therapies and to determine safety & efficacy of a combination of drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Favipiravir,Colchicine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : A2A Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under this collaboration, A2A designed the molecules using its proprietary computational AI-enabled drug discovery platform SCULPT™, which are currently being synthesized and will be evaluated by Laxai.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 08, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : A2A Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
